PCSK9抑制剂不良事件信号检测:全国序列对称性与全球失衡性分析
本研究利用法国全国健康系统数据库(SNDS)对2018-2023年PCSK9抑制剂起始者与依折麦布起始者进行序列对称性分析(SSA),共纳入36,163例PCSK9i起始者和34,269例依折麦布起始者,分析700个结局。SSA识别出吸入性糖皮质激素和集落刺激因子两个潜在信号,但WHO VigiBase未检测到相关信号,提示可能源于残留指示偏倚或混杂因素。
要点
- 法国SNDS数据库SSA分析识别出PCSK9i与吸入性糖皮质激素及集落刺激因子起始的两个潜在信号。
- 上述信号在WHO VigiBase失衡性分析中未重复,提示可能为残留指示偏倚或混杂。
- PCSK9i大规模真实世界安全性评估未发现明确新的安全信号。
核心结论
- 基于法国SNDS的SSA和WHO VigiBase的失衡性分析,PCSK9i仅识别出两个潜在信号,且均可能为残留指示偏倚或混杂因素所致。
研究设计与样本
- 研究采用序列对称性分析(SSA),使用法国全国健康系统数据库(SNDS),纳入2018-2023年PCSK9i起始者并与依折麦布起始者匹配。
- 对 designated medical events(DMEs)相关结局,在WHO药物警戒数据库VigiBase中进行失衡性分析以补充评估。
主要发现
- SSA共分析700个结局,识别出两个潜在信号:吸入性糖皮质激素(ATC-III)起始(SRc: 1.25 [1.16-1.38];SRa: 1.19 [1.06-1.35])和集落刺激因子(ATC-III)起始(SRc: 4.22 [2.81-6.71];SRa: 2.25 [1.37-4.17])。
- 上述信号在对应ATC-IV类别中重复出现。
- VigiBase中未检测到相关信号。
关键数值与推荐
- SSA中潜在安全信号定义为粗序列比(SRc)和依折麦布校正序列比(SRa)的95%置信区间下限均大于1。
临床怎么用
- 临床使用PCSK9i时,无需基于本研究新增特定安全信号警告,但应关注患者合并用药及基础疾病可能带来的混杂。
局限性
- 研究仅基于法国行政数据库和自发报告数据库,可能受残留指示偏倚和混杂因素影响。
- SSA识别的信号在VigiBase中未重复,提示信号可能为假阳性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIM: Despite the increasing use of proprotein convertase subtilisin/kexin type 9-inhibitors (PCSK9i), their safety assessment from large real-world databases remains limited. We aimed to perform a large-scale safety signals detection study regarding PCSK9i. METHODS: A sequence symmetry analysis (SSA) was conducted using the French nationwide health system databases (SNDS); PCSK9i initiators (2018-2023 time-period) were matched to ezetimibe ones, to control for temporal trends and potential indication bias. Outcomes of interest included all designated medical events (DMEs) and all drug classes considered by Anatomical Therapeutic Chemical (ATC) classification levels III and IV. In SSAs, potential safety signals for PCSK9i were defined as the combination of both a crude sequence ratio (SRc) and an ezetimibe-adjusted one (SRa) with a 95% confidence interval (CI) lower limit exceeding 1. For the outcomes corresponding to DMEs, disproportionality analyses were performed in the World Health Organization (WHO) pharmacovigilance database VigiBase® to complete the assessment. RESULTS: In total, sequence symmetries could be studied for 36,163 PCSK9i initiators and 34,269 ezetimibe ones. Over the 700 outcomes analyzed, two potential signals were identified via SSA, that related to ATC-III drug initiations for inhaled glucocorticoids (SRc: 1.25 [1.16-1.38]; SRa: 1.19 [1.06-1.35]) and colony stimulating factors (SRc: 4.22 [2.81-6.71]; SRa: 2.25 [1.37-4.17]); they were duplicated when considering the corresponding ATC-IV classes. No related signal was detected in VigiBase®. CONCLUSIONS: This study, combining analyses from large medico-administrative and spontaneous reports databases, identified only two potential signals relating to PCSK9i. Both appeared to be linked to residual indication bias or confounding factors.
引用
- Viguier T, Bezin J, Hlavaty A, et al. Signal Detection of Adverse Events Associated with PCSK9 Inhibitors: A Nationwide Sequence Symmetry and Combined Worldwide Disproportionality Analysis. Drug Saf. 2026. PMID: 42771263. doi:10.1007/s40264-026-01731-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。